HistoWiz
Private Company
Total funding raised: $8.5M
Overview
Founded in 2013, HistoWiz has established itself as a leading service provider in the research histopathology and digital pathology space, leveraging automation to deliver results in as few as three days. Its core offering integrates traditional lab services (histology, IHC/IF) with a digital platform for slide management, analysis, and collaboration, backed by a large network of board-certified pathologists. The company targets academic, biotech, and pharmaceutical researchers, aiming to accelerate preclinical research and drug development through faster, data-rich histopathology workflows.
Technology Platform
PathologyMap™: A cloud-based digital pathology platform for whole slide image management, viewing, annotation, sharing, and AI-driven analysis/QC tools, integrated with automated histology lab services.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
HistoWiz competes with other specialized preclinical histology CROs (e.g., Charles River Laboratories' pathology services, Labcorp's preclinical services), academic core facilities, and standalone digital pathology software vendors. Its key differentiators are its guaranteed 3-day turnaround, integrated digital platform, and extensive pathologist network.